<DOC>
	<DOCNO>NCT02982954</DOCNO>
	<brief_summary>To investigate safety Nivolumab combination Ipilimumab subject previously untreated advanced metastatic Renal Cell Cancer .</brief_summary>
	<brief_title>A Study Evaluate Safety Nivolumab Ipilimumab Subjects With Previously Untreated Advanced Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com 1 . Type Participant Target Disease Characteristics 1 . Advanced metastatic RCC 2 . Histologically confirm , previously untreated ( treatmentnaive ) RCC 3 . No prior systemic therapy RCC except one prior adjuvant neoadjuvant therapy completely resectable RCC 4 . Measurable disease per RECIST 1.1 . Subject must extracranial metastasis measurable disease 5 . Karnofsky Performance Status ( KPS ) least 70 % Cohort 1 , 2 , 3 ; KPS 5060 % Cohort 4 6 . Tumor tissue need receive central vendor ( block unstained slide ) . Note : Fine Needle Aspiration ( FNA ) bone metastases sample acceptable submission . 1 . Medical Conditions 1 . Subjects active autoimmune disease history know autoimmune disease 2 . Prior malignancy active within previous 3 year except locally curable cancer apparently cure 3 . Known HIV AIDSrelated illness 4 . Any positive test hepatitis B hepatitis C virus indicate acute chronic infection . 2 . Prior/Concomitant Therapy 1 . Prior systemic treatment metastatic setting Vascular epithelial growth factor ( VEGF ) VEGF receptor target therapy 2 . Prior treatment antiProgrammed Death ( PD ) 1 , antiPDL1 , antiPDL2 , anticluster differentiation 137 ( CD137 ) , anticytotoxic Tlymphocyteassociated antigen 4 ( CTLA4 ) antibody , antibody drug specifically target Tcell costimulation checkpoint pathway . This include utilization agent neoadjuvant adjuvant setting . 3 . Anticancer therapy le 28 day prior first dose study drug palliative , focal radiation therapy le 14 day prior first dose study drug . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>